^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Kaitanni (cadonilimab) (PD1 inhibitor, CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1300P - A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
Published date:
09/13/2021
Excerpt:
This is a single-arm, two part, phase Ib/II study. All patients were stage IIIB/C or IV NSCLC….Among them, the ORR was 80% (4/5) in non-squamous NSCLC….AK104 in combination with anlotinib showed favorable antitumor activity and an acceptable safety profile in treatment-naïve patients with PD-L1 TPS≥1% NSCLC.
